Faran S.A. and Quantum Genomics
On June 30, 2021, the Greek pharmaceutical company Faran has proceeded to an exclusive collaboration with the biopharmaceutical company Quantum Genomics, for the development and distribution of the innovative pharmaceutical product Firibastat for the treatment of resistant hypertension and heart failure. This is a significant investment by Faran in the research and development of an […..]
Faran S.A. and STADA Arzneimittel AG
FARAN S.A. and STADA Arzneimittel AG, are pleased to announce the beginning of their cooperation in the field of Osteoporosis. More specifically, in the context of the cooperation with STADA Arzneimittel AG, FARAN undertakes the promotion and distribution in Greek market of Movymia, STADA’s first first bio-similar Teriparatide. Movymia is indicated for the treatment of […..]
Faran S.A. and Atnhas
Faran S.A. is pleased to announce its cooperation with the pharmaceutical company Atnhas in the field of Osteoporosis, which concerns the original pharmaceutical product Bonviva (Ibandronic Acid). Bonviva is used to treat osteoporosis (a disease that makes bones brittle) in postmenopausal women at risk of fractures. Ibandronic acid is a bisphosphonate with high activity, belonging […..]
Faran S.A. and Meiji
Faran S.A. is pleased to announce its collaboration with the Japanese pharmaceutical company MEIJI in the field of infections, which concerns the launch in the Greek market of the original pharmaceutical product Spectracef (Ceftidoren Pivoxil). Spectracef (Ceftidoren Pivoxil) is a 3rd generation oral cephalosporin, a research product of the company MEIJI for the treatment of […..]
Faran S.A. and Sandoz
Faran S.A. and Sandoz, a member of the Novartis Group, after their successful cooperation, are pleased to announce the expansion of their cooperation, undertaking the promotion and distribution of another product with the active ingredient Epoetin Alfa. This collaboration will strengthen the leading position of Faran S.A. in the field of Biotechnology, as Sandoz is […..]
Faran S.A. & Novartis (Hellas) S.A.
Faran S.A. and Novartis (Hellas) S.A. are pleased to announce the beginning of their collaboration in the field of therapeutic oncology. More specifically, in the context of its cooperation with Novartis, Faran undertakes the promotion and distribution in the Greek market of its formulations Novartis TYVERB (Lapatinib) and ZYKADIA (Ceritinib). TYVERB (Lapatinib) is indicated for […..]